Kinase/Phosphatase-Targeted Antibody Drug DiscoveryINQUIRY
Creative BioMart has unparalleled expertise and innovation to provide our customers with integrated kinase/phosphatase-targeted antibody drug discovery solutions from genes to therapeutic antibody candidates. Our highly skilled scientists strive to develop streamlined processes and use reliable data to guide our customers throughout the whole discovery process. Our customized solutions that can start from any stage of the process will be delivered according to customer needs.
Since the approval of the first monoclonal antibodies, antibody engineering has evolved considerably. In recent years, therapeutic antibodies have become the predominant class of promising drugs in the pharmaceutical industry because of their high specificity. Antibodies have been used to treat a variety of diseases, such as cancer, infectious diseases, and immunological diseases. Current therapeutic antibodies can be broadly classified into two categories. One is naked antibodies used directly for disease treatment, and the other one is antibodies that are additionally modified to enhance their therapeutic value. As important therapeutic targets, kinases and phosphatases have also attracted attention in antibody therapies. Advances in kinase/phosphatase biology have led to an explosion in the number of antibody drug pipelines, especially those directed against kinases. Exploring phosphorylation networks will greatly advance the clinical applications of antibodies.
Figure 1. PTK7-targeted antibody-drug conjugates (PTK7-ADC). (Katoh M., 2017)
Discovery of Therapeutic Monoclonal Antibodies
Monoclonal antibodies have rapidly taken hold in the pharmaceutical industry since they were recognized as having great therapeutic potential. Creative BioMart offers a variety of immunization-dependent and immunization-independent techniques for the discovery of high-affinity monoclonal antibodies against a broad variety of kinase and phosphatase targets. Our expertise and state-of-the-art platform in antibody discovery can help our customers accelerate their pipeline.
Antibody-Drug Conjugate Development
ADCs which combine the targeting ability of monoclonal antibodies with highly potent cytotoxic agents have become the fastest growing anti-cancer drugs. Creative BioMart offers integrated solutions covering every step in ADC development to promote the development of kinase/phosphatase-targeted cancer therapies. We are committed to providing our customers with customized and streamlined solutions to accelerate the selection of optimal ADC candidates for their target of interest.
Discovery of Therapeutic Bispecific Antibodies
Bispecific antibodies (BsAbs) can bind two antigens or two epitopes of the same antigen and therefore have a wide range of applications in cancer immunotherapy as well as in the treatment of many other diseases. Creative BioMart has focused on cutting-edge BsAb strategies for years and is proud to offer our customers one-stop solutions to drive the discovery of BsAb as novel therapeutics for the treatment of kinases and phosphatases associated diseases.
Comprehensive Methodologies for Antibody Drug Discovery
Creative BioMart offers innovative and diverse strategies and technology platforms spanning all stages of antibody drug discovery, including but not limited to hybridoma generation, phage display, single B cell screening, antibody humanization, affinity maturation, and best-in-class transgenic animals. High-affinity antibodies selected by our experienced scientists will fulfill our customers’ requirements as possible and make their transition from lead to drug that much faster.
Antigen Preparation and Characterization
Custom Monoclonal Antibody Production
Phosphorylation-Specific Antibody Production
In Vitro Kinase Screening & Profiling
In Vitro Phosphatase Screening & Profiling
Creative BioMart is a trusted solution provider with many years of experience in kinase/phosphatase biology research and drug development. We have always been committed to providing our customers with high-quality products and customized services to accelerate their cutting-edge research and drug development pipeline. We fully support your project every step of the way to success.
Contact us to find out how our scientists can help you with your drug development project.
- Katoh M. Antibody-drug conjugate targeting protein tyrosine kinase 7, a receptor tyrosine kinase-like molecule involved in WNT and vascular endothelial growth factor signaling: effects on cancer stem cells, tumor microenvironment and whole-body homeostasis. Annals of translational medicine, 2017, 5(23).
- Lu R M, et al. Development of therapeutic antibodies for the treatment of diseases. Journal of biomedical science, 2020, 27(1): 1-30.